Azenosertib
- Generic Name
- Azenosertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C29H34N8O2
- CAS Number
- 2376146-48-2
- Unique Ingredient Identifier
- 9J13XU96Z1
- Associated Conditions
- -
- Associated Therapies
- -
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
Phase 1
Recruiting
- Conditions
- Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Metastatic Gastroesophageal Junction AdenocarcinomaUnresectable Gastric CarcinomaUnresectable Gastroesophageal Junction AdenocarcinomaUnresectable Malignant Solid NeoplasmClinical Stage III Gastric Cancer AJCC v8Locally Advanced Gastroesophageal Junction AdenocarcinomaClinical Stage IV Gastric Cancer AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Locally Advanced Gastric Carcinoma
- Interventions
- Drug: AzenosertibProcedure: Biospecimen CollectionProcedure: BiopsyProcedure: Computed TomographyProcedure: EchocardiographyProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition ScanBiological: Trastuzumab Deruxtecan
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT06364410
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath